Hormonal Approach for Postmenopausal Vulvovaginal Atrophy [PDF]
Frontiers in Reproductive Health, 2021 Menopause is a physiological and progressive phenomenon secondary to decreased ovarian follicular reserve that significantly affects the genital tract. Although postmenopausal vulvovaginal atrophy primarily affects postmenopausal women, it is also seen ...
Ana Paula Ferreira Costa +7 more
doaj +6 more sources
GRACE-trial: a randomised active-controlled trial for vulvovaginal atrophy in patients with breast cancer on endocrine therapy – study protocol [PDF]
BMJ Open, 2023 Introduction Breast cancer is the most common cancer type in women worldwide. Due to hormone receptor positivity in the majority of the breast cancer tumours is endocrine therapy a crucial part in the treatment landscape of breast cancer.
Glenn Vergauwen +6 more
doaj +4 more sources
Vulvovaginal Atrophy Following Treatment for Oncogynecologic Pathologies: Etiology, Epidemiology, Diagnosis, and Treatment Options [PDF]
MedicinaVulvovaginal atrophy, characterized by the thinning of vaginal mucosa typically resulting from reduced estrogen levels, is frequently exacerbated by oncogynecologic treatments such as chemotherapy, hormonal therapy, radiotherapy, or surgery.
Ramunė Narutytė +2 more
doaj +3 more sources
Use of Moisturizers and Lubricants for Vulvovaginal Atrophy [PDF]
Frontiers in Reproductive Health, 2021 The estrogen decrease in postmenopausal women results in functional and anatomical changes in the genitourinary tract. The most prevalent and bothersome symptoms are vaginal dryness, dyspareunia, and reduced lubrication, which can significantly affect ...
Ayane Cristine Alves Sarmento +7 more
doaj +6 more sources
Lubricants application in vulvovaginal atrophy [PDF]
РМЖ. Мать и дитя, 2018 Lubricants application in vulvovaginal atrophy Yu.E. Dobrokhotova, S.A. Khlynova Pirogov Russian National Research Medical University, Moscow, Russian Federation Interim periods as well as the postmenopausal period are extremely important in ...
Yu.E. Dobrokhotova, S.A. Khlynova
doaj +3 more sources
Comment on Jankovic et al. Understanding the Benefits of CO2 Laser Treatment for Vulvovaginal Atrophy. Medicina 2024, 60, 1059 [PDF]
MedicinaWe write with concerns regarding the recent publication of “Understanding the Benefits of CO2 Laser Treatment for Vulvovaginal Atrophy” [...]
Catherine Broomfield +2 more
doaj +3 more sources
Update on alternative therapies for vulvovaginal atrophy
Patient Preference and Adherence, 2011 Janet A Chollet1,2 1Beth Israel Deaconess Medical Center, Boston, 2Pear Tree Pharmaceuticals, Waltham, MA, USA Abstract: Although systemic absorption of estrogen with local treatment for vulvovaginal atrophy (VVA) is most likely to be negligible, it is ...
Chollet J
doaj +6 more sources
Topical Spermidine Hyaluronate (Spd-HA) in Vulvovaginal Atrophy: A Preliminary Study [PDF]
MedicinaBackground and Objectives: Genitourinary syndrome of menopause (GSM), previously termed vulvovaginal atrophy (VVA), is a prevalent hypoestrogenic condition characterized by genital, sexual, and urinary symptoms. Although hormonal therapies are effective,
Irene Porcari +9 more
doaj +3 more sources
International Journal of Women's Health, 2013 Sharon J Parish,1 Rossella E Nappi,2 Michael L Krychman,3 Susan Kellogg-Spadt,4 James A Simon,5 Jeffrey A Goldstein,6 Sheryl A Kingsberg7 1Albert Einstein College of Medicine, Bronx, NY, USA; 2Department of Obstetrics and Gynecology, IRCCS Policlinico ...
Parish SJ +6 more
doaj +9 more sources
Impact Of Vulvovaginal Atrophy Of Menopause In Spanish Women: Prevalence And Symptoms According To The EVES Study [PDF]
Sexual Medicine, 2019 Introduction: The prevalence of menopausal women with confirmed vulvovaginal atrophy (VVA) oscillates between 67–98%. Aim: To assess the prevalence of postmenopausal women with VVA confirmed by gynecologic clinical assessment among all women attending ...
Santiago Palacios, MD, PhD +27 more
doaj +3 more sources